A systematic review was undertaken to identify trials comparing any of the interventions to treat nAMD reporting mean change from baseline in best corrected visual acuity (BCVA). A NMA of the studies was carried out using WinBugs. Identified studies often reported results at multiple time points and mean change from baseline in BCVA was modelled at multiple time points. To reflect changes in treatment frequency over time and the equivalence of some posologies at some time points, three difference networks were employed. These are depicted in Figure 1 .
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Green nodes are the EU licensed posologies of interest
To account for the time structure within the data a number of models as proposed by Dakin et al. (5) and Ding and Fu (6) were applied and the deviance information criterion (DIC) was used to select the most appropriate model. Model options included controlling for baseline differences in BCVA and grouping of posologies. The model selected was one proposed by Ding and Fu (6) in which the mean relative treatment effect with time follows a parametric model. Neovascular (wet) age related macular degeneration (nAMD) is a leading cause of vision loss globally (1). In the United Kingdom (UK), the prevalence of nAMD is 284,000 with 39,700 new cases a year (2) . In the United States the prevalence of nAMD is 1.2 million with more than 200,000 new cases a year (3). The prevalence of nAMD is also expected to grow with increasing life expectancy and it is forecast that the prevalence of nAMD is likely increase significantly over coming years (3, 4) . 
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